Additive anti-allergic effects of anti-interleukin-33 and anti-Siglec-F treatments in a murine model of allergic asthma

5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background: anti-interleukin-33 (anti-iL-33) and anti-Siglec-F antibodies have potent anti-allergic effects on murine allergic asthma and rhinitis and induce eosinophil apoptosis. Objective: we aimed to determine whether post-sensitization with anti-iL-33/anti-Siglec-F treatments exhibited more potent effects compared to individual treatments in a murine allergic asthma model. Material and methods: Twenty-five BaLB/c mice were separated into five groups (n = 5): group a (control), group B (ovalbumin [oVa] challenge), group C (oVa + anti-iL-33), group D (oVa + anti-Siglec-F), and group E (oVa + anti-iL-33 + anti-Siglec-F). Serum total/oVa-specific IGE, bronchoalveolar lavage (BaL) inflammatory cells and cytokines (iL-4 and iL-5), histopathological lung properties, and airway hyperreactivity were compared. Results: ovalbumin challenge induced strong immune and inflammatory responses with > 6-fold IGE level increases; 10- to 25-fold BaL eosinophil, neutrophil, and lymphocyte count increases; and > 1.5-fold IL-4 and IL-5 level increases (p < 0.05). whereas anti-iL-33 reduced neutrophil counts, anti-Siglec-F and anti-IL-33/anti-Siglec-F reduced both eosinophil and neutrophil counts (p < 0.05). individual treatments reduced oVa-mediated bronchiolar infiltration by 50% (p <0.05). ovalbumin challenge increased airway hyperreactivity by 4-fold (group B; 2000.0 ±671.8% increase in Penh) compared to controls (group A; 445.7 ±33.5% increase in Penh) (p = 0.016). The anti-iL-33 (group C: 1579.4 ±973.6% increase in Penh) and anti-Siglec-F (group D: 930.4 ±236.5%) groups demonstrated significantly reduced hyperreactivity (p = 0.029). anti-iL-33/anti-Siglec-F therapy showed synergism towards neutrophil counts, IL-5 concentrations, bronchial infiltration, and hyperreactivity (p < 0.05). Conclusions: Combination treatment with anti-IL-33/anti-Siglec-F had more potent anti-allergic effects, reducing eosinophilic infiltration through their additive effects in a murine allergic asthma model.

Cite

CITATION STYLE

APA

Jang, T. Y., Park, C. S., Jeon, M. S., Heo, M. J., Na, K., & Kim, Y. H. (2014). Additive anti-allergic effects of anti-interleukin-33 and anti-Siglec-F treatments in a murine model of allergic asthma. Central European Journal of Immunology, 39(4), 426–433. https://doi.org/10.5114/ceji.2014.47724

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free